Use of cxcl6 chemokine in the prevention or repair of cartilage defects
CA 2533124 C · Owner: Tigenix N.V. · Inventors: Dell'Accio, Francesco; Luyten, Frank; De Bari, Cosimo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 12, 2004 and granted January 28, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 12, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 12, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.